Embecta Corp. revenue
Embecta Corp.'s revenue was $1.08bn in fiscal 2025, down 3.8% on the year before. Since fiscal 2020 ($1.09bn) it has grown at a compound -0.1% a year. Over the last twelve months it was $1.02bn.
Revenue history
| Fiscal year | 2020Sept 2020 | 2021Sept 2021 | 2022Sept 2022 | 2023Sept 2023 | 2024Sept 2024 | 2025Sept 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Revenue | 1,086 | 1,165 | 1,130 | 1,121 | 1,123 | 1,080 | 1,019 |
| Growth on the year before | — | +7.4% | −3.1% | −0.8% | +0.2% | −3.8% | — |
| Gross profit | 763 | 800 | 775 | 750 | 735 | 677 | 601 |
| Gross margin | 70.3% | 68.7% | 68.6% | 66.9% | 65.5% | 62.6% | 59.0% |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Pen Needles | $784M | 72.6% | ▼ 7.1% |
| Safety | $138M | 12.8% | ▲ 6.5% |
| Syringes | $125M | 11.5% | ▼ 1.3% |
| Manufacturing Facility | $19.9M | 1.8% | ▲ 55.5% |
| Other | $14M | 1.3% | ▲ 35.9% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $579M | 53.6% | ▼ 4.6% |
| Outside the US | $501M | 46.4% | ▼ 2.8% |
From Embecta Corp.'s 10-K filed November 25, 2025, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Embecta Corp. | $1.02bn | -7.6% | -2.9% |
| UFP Technologies Inc | $632m | 7.3% | 17.8% |
| ICU Medical Inc | $2.16bn | -9.0% | -2.0% |
| Organogenesis Holdings Inc. | $457m | 6.5% | 0.0% |
| Envista Holdings Corp | $2.86bn | 11.9% | 3.4% |
| West Pharmaceutical Services | $3.40bn | 12.6% | 5.1% |
Compare with peers
- UFP Technologies Inc revenue
- ICU Medical Inc revenue
- Organogenesis Holdings Inc. revenue
- Envista Holdings Corp revenue
- West Pharmaceutical Services revenue
Head to head: EMBC vs UFPTEMBC vs ICUIEMBC vs ORGO
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies